TAMOVAC-01-MZ
Status:Completed
Phase:I
Principal Investigator(s):Ilesh Jani, Nafissa Osman
Objective:The study aims to determine safety and immunogenicity of the DNA-vaccine at a dose of 600µg and 1200µg delivered id in combination with MVA-CMDR boost im.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
Description600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
Mode of DeliveryIntramuscular
ARMsExperimental
Description1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT01407497
Trial Sponsors:
European and Developing Countries Clinical Trials Partnership (EDCTP), Instituto Nacional de Saude Mozambique, Swedish Institute for Infectious Disease Control (SMI)
Start Date
End Date
August 31, 2011
August 31, 2013
Enrollment:25
Age range:
18 Years ↔
26 Years
Population:Cisgender Men, Cisgender Women